Literature DB >> 19012991

High lifetime risk of cancer in primary sclerosing cholangitis.

Marian M H Claessen1, Frank P Vleggaar, Kristien M A J Tytgat, Peter D Siersema, Henk R van Buuren.   

Abstract

BACKGROUND/AIMS: Primary sclerosing cholangitis (PSC) patients are at risk for developing cholangiocarcinoma (CCA) and colorectal carcinoma (CRC). Our aim was to assess the risk of malignancies and their influence on survival.
METHODS: Data from PSC patients diagnosed between 1980 and 2006 in two university hospitals were retrieved. The Kaplan-Meier method and a time-dependent Cox regression model were used to calculate risks of malignancies and their influence on survival.
RESULTS: Two hundred and eleven patients were included, 143 (68%) were male and 126 (60%) had inflammatory bowel disease (IBD). Median transplantation-free survival was 14 years. The risk of CCA after 10 and 20 years was 9% and 9%, respectively. In patients with concomitant IBD the 10-year and 20-year risks for CRC were 14% and 31%, which was significantly higher than for patients without IBD (2% and 2% (P=0.008)). CCA, cholangitis, and age at entry were independent risk factors for the combined endpoint death or liver transplantation. Risk factors for the endpoint death were CCA, CRC, age, and symptomatic presentation.
CONCLUSIONS: Patients with PSC and IBD have a high long-term risk of developing CRC and this risk is about threefold higher than the risk for CCA. Both malignancies are associated with decreased survival.

Entities:  

Mesh:

Year:  2008        PMID: 19012991     DOI: 10.1016/j.jhep.2008.08.013

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  98 in total

1.  Unique Inflammatory Bowel Disease Phenotype of Pediatric Primary Sclerosing Cholangitis: A Single-Center Study.

Authors:  Henry Shiau; Faith D Ihekweazu; Mansi Amin; Tatiana Fofanova; Tamir Miloh; Richard Kellermayer
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-10       Impact factor: 2.839

Review 2.  Hyaluronan in immune dysregulation and autoimmune diseases.

Authors:  Nadine Nagy; Hedwich F Kuipers; Payton L Marshall; Esther Wang; Gernot Kaber; Paul L Bollyky
Journal:  Matrix Biol       Date:  2018-04-04       Impact factor: 11.583

Review 3.  Update in the Care and Management of Patients with Primary Sclerosing Cholangitis.

Authors:  Mai Sedki; Cynthia Levy
Journal:  Curr Gastroenterol Rep       Date:  2018-06-09

Review 4.  Cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Lancet       Date:  2014-02-26       Impact factor: 79.321

Review 5.  A Comprehensive Review of the Diagnosis and Pharmacological Management of Crohn's Disease in the Elderly Population.

Authors:  David Kim; Sasha Taleban
Journal:  Drugs Aging       Date:  2019-07       Impact factor: 3.923

6.  Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease.

Authors:  Ashwin N Ananthakrishnan; Andrew Cagan; Vivian S Gainer; Su-Chun Cheng; Tianxi Cai; Peter Szolovits; Stanley Y Shaw; Susanne Churchill; Elizabeth W Karlson; Shawn N Murphy; Isaac Kohane; Katherine P Liao
Journal:  J Crohns Colitis       Date:  2014-02-19       Impact factor: 9.071

Review 7.  Diagnosis and management of primary sclerosing cholangitis-perspectives from a therapeutic endoscopist.

Authors:  Kunjam Modha; Udayakumar Navaneethan
Journal:  World J Hepatol       Date:  2015-04-18

Review 8.  Endoscopic and pathological aspects of colitis-associated dysplasia.

Authors:  Fiona D M van Schaik; G Johan A Offerhaus; Marguerite E I Schipper; Peter D Siersema; Frank P Vleggaar; Bas Oldenburg
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09-22       Impact factor: 46.802

Review 9.  Primary sclerosing cholangitis: diagnosis, prognosis, and management.

Authors:  Siddharth Singh; Jayant A Talwalkar
Journal:  Clin Gastroenterol Hepatol       Date:  2013-02-27       Impact factor: 11.382

10.  Carcinoembryonic Antigen Level in Primary Sclerosing Cholangitis Is Not Influenced by Dominant Strictures or Bacterial Cholangitis.

Authors:  Andreas Wannhoff; Christian Rupp; Kilian Friedrich; Johannes Knierim; Christa Flechtenmacher; Karl Heinz Weiss; Wolfgang Stremmel; Daniel N Gotthardt
Journal:  Dig Dis Sci       Date:  2016-12-09       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.